PIONEER
ACADEMIC PUBLISHING LIMITED

Current Research in Medical Sciences
ISSN 2958-0390
www.pioneerpublisher.com/crms
Volume 4 Number 1 January 2025

Evaluating the Effectiveness of Genetic Testing for Personalized Treatment in Non-Small Cell Lung Cancer (NSCLC) in South Korea

Bowen Chen[1]

[1] University of Ulsan, Ulsan, South Korea
Correspondence: Bowen Chen, University of Ulsan, Ulsan, South Korea.

doi:10.56397/CRMS.2025.01.05

Abstract

Non-Small Cell Lung Cancer (NSCLC) represents the most prevalent type of lung cancer globally, and its treatment has been revolutionized through the integration of genetic testing, which enables personalized treatment strategies. This paper examines the effectiveness of genetic testing in NSCLC, particularly in the context of South Korea, where significant advancements in precision oncology have been made. The study explores the role of genetic testing in identifying actionable mutations such as EGFR, ALK, and ROS1, and how these genetic profiles influence treatment decisions, particularly the use of tyrosine kinase inhibitors (TKIs) and immunotherapy. Through an analysis of clinical outcomes, including patient survival rates, progression-free survival, and quality of life, the paper highlights the benefits of genetic testing in improving patient care. Furthermore, challenges such as the accessibility, affordability, and technical limitations of genetic testing are discussed, along with the need for greater integration of genetic testing in clinical practice. The ethical implications surrounding patient autonomy, informed consent, and the use of genetic data are also explored. By addressing these issues, this paper aims to provide a comprehensive understanding of the role of genetic testing in NSCLC treatment and its potential to enhance clinical outcomes in South Korea.

Keywords: Non-Small Cell Lung Cancer (NSCLC), genetic testing, personalized treatment, EGFR mutations, ALK rearrangements, ROS1 fusions, Tyrosine Kinase Inhibitors (TKIs)

1. Introduction

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all cases globally. In South Korea, NSCLC represents a significant public health challenge, with a notable increase in incidence due to both environmental factors, such as air pollution and smoking, as well as the country's aging population. The epidemiological shift in South Korea highlights the need for more effective, individualized treatment strategies that go beyond traditional chemotherapy.

Personalized treatment has become a cornerstone in the management of NSCLC, revolutionizing the way oncologists approach care for patients. Unlike conventional treatment, which follows a generalized protocol, personalized therapy tailors the treatment based on the molecular and genetic profile of the

patient's tumor. This shift toward personalized medicine is particularly relevant in NSCLC, as distinct genetic mutations and alterations, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, and ROS1 fusions, significantly influence the tumor's behavior and its response to therapy. Personalized treatment ensures that patients receive therapies specifically targeting the mechanisms driving their cancer, offering higher efficacy and reducing unnecessary side effects.

Genetic testing plays a pivotal role in the decision-making process for personalized NSCLC treatment. By identifying genetic mutations and biomarkers present in the tumor, genetic testing helps clinicians select the most appropriate targeted therapies. For example, EGFR mutations are commonly found in Asian populations, including South Korea, and patients with these mutations benefit from tyrosine kinase inhibitors (TKIs) such as gefitinib or osimertinib. Furthermore, genetic testing helps in the identification of patients eligible for immunotherapy based on biomarkers like PD-L1 expression levels. The integration of genetic testing into routine clinical practice allows for more precise and individualized treatment plans, improving patient outcomes and minimizing the trial-and-error approach traditionally associated with cancer therapy. Thus, genetic testing has become essential for optimizing treatment and improving survival rates in NSCLC patients in South Korea.

2. Genetic Testing Technologies Used in NSCLC

Genetic testing has become an integral part of the diagnostic and therapeutic process for Non-Small Cell Lung Cancer (NSCLC), allowing for the identification of key genetic mutations that significantly influence treatment decisions. These genetic alterations, such as EGFR mutations, ALK rearrangements, and ROS1 fusions, can determine the most effective targeted therapies and contribute to better patient outcomes. Given the high prevalence of EGFR mutations in East Asian populations, including South Korea, the identification of these mutations is particularly crucial for personalizing NSCLC treatment.

EGFR mutations are among the most common genetic alterations found in NSCLC, particularly in patients who have never smoked or have a low smoking history. These mutations lead to the activation of the EGFR signaling pathway, which promotes tumor growth and resistance to conventional chemotherapy. Targeted therapies, such as tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, and osimertinib, have proven highly effective in treating patients with EGFR-mutant NSCLC. ALK rearrangements, though less common, occur in a subset of NSCLC patients, especially younger, non-smoking individuals. These rearrangements involve the fusion of the ALK gene with other genes, leading to abnormal protein production and tumor growth. ALK inhibitors such as crizotinib and alectinib have been shown to be highly effective in treating patients with ALK-positive NSCLC. Similarly, ROS1 fusions have been identified as another important driver of NSCLC, and targeted therapies like crizotinib have also shown promising results in treating patients with ROS1-positive tumors.

In South Korea, genetic testing for NSCLC is increasingly integrated into clinical practice. The two most commonly used techniques are Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), each with its own advantages and limitations.

Polymerase Chain Reaction (PCR) is a widely utilized molecular diagnostic tool in South Korea for detecting specific genetic mutations in NSCLC. PCR works by amplifying small amounts of DNA to detect specific mutations, such as those in the EGFR gene. This method is relatively simple, cost-effective, and provides results in a short period. PCR is especially useful for detecting well-known mutations, such as EGFR exon 19 deletions and L858R point mutations. However, PCR is a targeted technique, meaning it is designed to detect a limited set of mutations. This limitation makes it less suitable for comprehensive mutation profiling, especially in cases where unknown mutations might be present. Therefore, while PCR is effective for initial screening or known genetic alterations, it cannot capture the full spectrum of mutations in a patient's tumor, necessitating supplementary testing for more comprehensive analysis.

Next-Generation Sequencing (NGS) represents a more advanced and comprehensive approach to genetic testing in NSCLC. Unlike PCR, NGS allows for the simultaneous sequencing of multiple genes, providing a broader genetic

profile of the tumor. NGS can detect a wide range of genetic alterations, including EGFR mutations, ALK rearrangements, ROS1 fusions, and other potentially actionable mutations like KRAS and BRAF. This technique not only identifies the presence of specific mutations but also offers insight into the broader mutational landscape of the tumor, helping to inform more personalized treatment decisions. NGS is particularly beneficial for patients who may have rare or unknown mutations that are not covered by conventional PCR tests. Additionally, NGS is well-suited for identifying acquired resistance mutations, such as the T790M mutation in EGFR-positive NSCLC, which can be critical for choosing the appropriate second-line treatment.

However, NGS does have its challenges. It is more expensive and requires specialized equipment and expertise, which limits its accessibility in certain clinical settings. Moreover, the interpretation of NGS results can be complex due to the sheer volume of data generated, requiring advanced bioinformatics tools and skilled personnel. Additionally, NGS often takes longer to provide results compared to PCR, which can delay the initiation of treatment.

While PCR is advantageous in terms of cost, speed, and ease of use, it is limited in its ability to detect a wide range of mutations, making it less comprehensive for personalized treatment decisions. On the other hand, NGS offers a broader and more detailed genetic profile, providing crucial information for selecting personalized therapies, but it comes at a higher cost and with a longer turnaround time. Therefore, the choice between PCR and NGS often depends on the clinical context, available resources, and the need for comprehensive mutation analysis in NSCLC patients.

In summary, genetic testing technologies like PCR and NGS are essential in the management of NSCLC, especially in South Korea, where the implementation of targeted therapies based on genetic alterations has significantly improved treatment outcomes. While PCR remains the go-to method for detecting specific mutations due to its cost-effectiveness and speed, NGS is becoming increasingly important for comprehensive mutation profiling and personalized treatment plans. The continued integration of genetic testing into routine clinical practice in South Korea will be critical in optimizing treatment strategies and improving the overall survival rates of NSCLC patients.

3. Personalized Treatment Approaches Based on Genetic Testing

The advent of genetic testing has fundamentally transformed the treatment paradigm for Non-Small Cell Lung Cancer (NSCLC), particularly through its ability to guide the selection of targeted therapies tailored to an individual's unique genetic profile. This approach, often referred to as "personalized" or "precision" medicine, ensures that patients receive treatments specifically designed to target the genetic alterations driving their cancer. By identifying specific mutations or molecular abnormalities in the tumor, genetic testing enables clinicians to move beyond standard chemotherapy regimens and employ therapies that are more effective and less toxic.

Genetic testing informs targeted therapy by identifying mutations that are crucial drivers of cancer growth. For instance, epidermal growth factor receptor (EGFR) mutations are found in a substantial proportion of NSCLC patients, especially in East Asian populations such as South Korea. These mutations result in the overactivation of the EGFR signaling pathway, which promotes cancer cell proliferation. Patients with EGFR mutations are particularly responsive to tyrosine kinase inhibitors (TKIs), a class of targeted drugs that block the aberrant EGFR signaling. Commonly used TKIs include gefitinib, erlotinib, and osimertinib. The use of TKIs in EGFR-positive NSCLC patients has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) compared to traditional chemotherapy, with fewer side effects, making it a highly effective treatment strategy.

In addition to EGFR mutations, anaplastic lymphoma kinase (ALK) gene rearrangements are another key target for personalized therapy. ALK rearrangements lead to the production of abnormal proteins that drive cancer cell growth. The identification of ALK-positive NSCLC allows for the use of ALK inhibitors, such as crizotinib and alectinib, which are highly effective in stopping the cancer's progression. These targeted therapies have been shown to offer significant benefits in terms of both PFS and OS in ALK-positive patients, making them a cornerstone of personalized treatment for this subgroup.

Furthermore, ROS1 gene fusions, although less

common, also present a viable target for personalized therapy. Similar to ALK rearrangements, ROS1 fusions result in abnormal protein production that drives NSCLC. The targeted therapy crizotinib has been proven effective in treating patients with ROS1-positive tumors, offering another example of how genetic testing can guide treatment selection.

In South Korea, the use of genetic testing for NSCLC has become increasingly prevalent, with the national healthcare system incorporating it as a standard diagnostic tool in oncology. South Korea has been at the forefront of integrating precision medicine into clinical practice, with significant efforts in identifying genetic mutations such as EGFR and ALK. Personalized treatment approaches, based on genetic testing results, are now routinely employed to optimize therapeutic outcomes.

For example, in patients with EGFR mutations, first-line treatment typically involves the use of EGFR-targeted TKIs, with osimertinib being a preferred option for those with the T790M resistance mutation, a common mutation that develops after initial treatment with first-line TKIs. This targeted therapy has shown a substantial improvement in both PFS and OS, particularly in patients who previously failed chemotherapy or other targeted treatments.

In patients with ALK rearrangements, South Korean oncologists routinely administer crizotinib or alectinib, with subsequent lines of therapy, such as brigatinib or lorlatinib, being used as second or third-line options when resistance develops. This stepwise approach ensures that treatment remains effective even as the cancer evolves.

Additionally, immunotherapy has gained traction in South Korea, especially in patients with high PD-L1 expression. Immunotherapy, such as pembrolizumab or atezolizumab, harnesses the body's immune system to recognize and attack cancer cells. Genetic testing, particularly PD-L1 expression testing, has become an essential tool for selecting patients who are most likely to benefit from immunotherapy. Patients with high PD-L1 expression generally exhibit better responses to these therapies, which can extend survival, particularly in advanced or metastatic stages of NSCLC.

The selection of treatment based on genetic profiling has proven to be far superior to the traditional "one-size-fits-all" approach. Genetic profiling allows clinicians to select the most appropriate therapy from a range of options, including targeted therapies, immunotherapy, and chemotherapy, based on the specific genetic makeup of the tumor. This approach not only increases the likelihood of treatment success but also minimizes the side effects associated with therapies that are less likely to be effective.

For example, patients with KRAS mutations, another common genetic alteration in NSCLC, historically had fewer targeted options. However, recent advancements in targeted therapy for KRAS-mutant tumors, such as sotorasib, have begun to offer new hope for these patients. As a result, the ability to perform comprehensive genetic testing ensures that even patients with less common mutations have access to the most appropriate and effective treatments.

Overall, the personalized treatment approaches based on genetic testing for NSCLC in South Korea highlight the shift towards precision medicine, where each patient's treatment is informed by their individual genetic profile. This approach has led to improved treatment outcomes, reduced side effects, and a more efficient allocation of healthcare resources, demonstrating the profound impact of genetic testing on the management of NSCLC. By continuing to integrate genetic testing into routine clinical practice, South Korea is setting a strong precedent for precision oncology in lung cancer management, ensuring that patients receive the most effective and targeted therapies available.

4. Clinical Outcomes and Benefits of Genetic Testing in NSCLC

The integration of genetic testing into the management of Non-Small Cell Lung Cancer (NSCLC) has significantly improved patient outcomes, especially in terms of survival rates, progression-free survival (PFS), and quality of life. In South Korea, clinical studies evaluating the role of genetic testing have demonstrated that tailoring treatment based on genetic profiles results in more effective and personalized care. This approach has shifted the treatment paradigm from generalized chemotherapy to more targeted therapies, which offer better outcomes with fewer side effects.

Overview of Clinical Studies in South Korea Numerous clinical studies conducted in South

Korea have highlighted the benefits of genetic testing in NSCLC patients, particularly in identifying mutations such as EGFR, ALK rearrangements, and ROS1 fusions. These studies have established the foundation for incorporating genetic testing into routine clinical practice, contributing to improved treatment strategies and patient care.

One pivotal study in South Korea evaluated the clinical impact of EGFR mutation testing in NSCLC patients and demonstrated that patients with EGFR mutations who received tyrosine kinase inhibitors (TKIs) such as gefitinib or osimertinib experienced a significant improvement in progression-free survival compared to those treated with traditional chemotherapy. The study concluded that genetic testing for EGFR mutations should be a standard procedure in South Korean clinical settings, offering an evidence-based approach to treatment.

Similarly, studies focusing on ALK testing have shown that ALK inhibitors like crizotinib and alectinib are highly effective in treating patients with ALK-positive NSCLC. A clinical trial conducted in South Korea demonstrated that patients with ALK rearrangements had better response rates to these targeted therapies, with a significant extension in progression-free survival compared to patients who received conventional chemotherapy. These findings have reinforced the clinical utility of genetic testing in selecting appropriate therapies for ALK-positive patients.

Moreover, the role of genetic testing in the personalized use of immunotherapy has been evaluated in several studies. Specifically, testing for PD-L1 expression and mutational burden has been shown to predict patient responses to immune checkpoint inhibitors, such as pembrolizumab and atezolizumab. In patients with high PD-L1 expression, immunotherapy has demonstrated significantly better outcomes compared to chemotherapy, making genetic testing an indispensable part of treatment planning.

Impact on Patient Survival Rates, Progression-Free Survival, and Quality of Life The most profound benefit of genetic testing in NSCLC is its impact on patient survival rates. Studies in South Korea consistently show that targeted therapies, guided by genetic testing, offer substantial improvements in survival compared to traditional chemotherapy. For instance, EGFR-positive patients who receive first-line TKIs experience significantly higher overall survival rates. A landmark study published in South Korea demonstrated that patients treated with osimertinib (an EGFR TKI) had a median overall survival of more than 30 months, compared to just 19 months for those receiving chemotherapy. This marked improvement underscores the critical role of genetic testing in improving long-term survival.

In addition to overall survival, progression-free survival (PFS) has been notably improved through genetic testing. In the case of ALK-positive patients, the use of ALK inhibitors has extended PFS by several months. For example, patients who were treated with crizotinib had a median PFS of approximately 10 months, which increased to over 20 months with alectinib, highlighting the substantial benefit of personalized treatment.

The quality of life (QoL) of NSCLC patients has also improved with genetic testing and personalized treatment. Targeted therapies, such as TKIs and ALK inhibitors, are generally better tolerated than traditional chemotherapy. Patients on targeted therapy report fewer side effects, such as nausea, fatigue, and hair loss, leading to improved daily functioning and overall well-being. Studies conducted in South Korea have shown that patients receiving EGFR inhibitors have higher QoL scores, as they experience fewer chemotherapy-associated side effects, thus allowing them to maintain a higher level of normal activity.

Benefits of Early Detection of Mutations and the Introduction of Tailored Therapies The early detection of genetic mutations has proven to be a game-changer in the treatment of NSCLC. Genetic testing allows for the identification of actionable mutations, such as EGFR mutations, ALK rearrangements, and ROS1 fusions, at an early stage. Detecting these mutations early in the disease process enables clinicians to initiate personalized therapy at the onset of treatment, providing patients with the best possible chance for effective intervention.

Early detection also facilitates the use of first-line targeted therapies, which can significantly delay disease progression. For instance, patients with EGFR mutations who begin treatment with TKIs like gefitinib or erlotinib often experience extended periods of disease control and symptom relief, leading to

better outcomes and improved QoL. Additionally, early intervention with ALK inhibitors in patients with ALK rearrangements has been shown to delay the onset of resistance and prevent rapid disease progression, offering patients months or even years of disease control.

Another advantage of early mutation detection is the ability to tailor treatment to the individual patient's needs, reducing the use of less effective and more toxic therapies. This personalized approach not only improves survival rates and PFS but also minimizes the adverse effects associated with inappropriate or ineffective treatments. By identifying the most appropriate targeted therapy early, genetic testing reduces the need for trial-and-error approaches, ultimately enhancing patient satisfaction and treatment adherence.

In summary, genetic testing has proven to be a critical tool in improving clinical outcomes for NSCLC patients in South Korea. Studies have consistently demonstrated that personalized treatments based on genetic profiling lead to improved survival rates, extended progression-free survival, and a better quality of life. The early detection of mutations allows for the initiation of tailored therapies, providing substantial clinical benefits and making genetic testing an indispensable component of modern cancer care. As the use of genetic testing continues to expand, its role in optimizing NSCLC treatment is likely to increase, further improving patient outcomes and revolutionizing cancer care in South Korea.

5. Challenges and Barriers in the Implementation of Genetic Testing

While genetic testing has revolutionized the treatment of Non-Small Cell Lung Cancer (NSCLC), its widespread adoption in South Korea faces several challenges and barriers. These obstacles include issues related to accessibility and affordability, technical and logistical barriers, and the need for greater integration of genetic testing into routine clinical practice across diverse healthcare settings. Despite significant progress, these challenges must be addressed to maximize the potential of genetic testing in optimizing NSCLC treatment outcomes.

Issues Related to Accessibility and Affordability of Genetic Testing in South Korea

Although South Korea boasts a well-developed healthcare system, accessibility and affordability remain significant barriers to the widespread use of genetic testing for NSCLC. Genetic testing can be expensive, especially when comprehensive panels like Next-Generation Sequencing (NGS) are used to detect a wide range of mutations and genetic alterations. While PCR-based tests, such as those for EGFR mutations, are more affordable and commonly used, the costs associated with advanced genetic testing methods, such as NGS, can be prohibitive for many patients, particularly those from lower socio-economic backgrounds or rural areas. This discrepancy creates disparities in treatment accessibility, with patients who cannot afford genetic testing being less likely to receive personalized treatment based on genetic profiling.

Furthermore, the cost of targeted therapies prescribed after genetic testing—such as EGFR inhibitors or ALK inhibitors—can add to the financial burden on patients. While these therapies are highly effective, they are often not covered entirely by public insurance, which may limit patient access to these life-saving treatments. As a result, the affordability of both genetic testing and subsequent therapies is a critical challenge that needs to be addressed to ensure equitable access to personalized cancer care.

Technical and Logistical Barriers

In addition to financial barriers, technical and logistical challenges also hinder the effective implementation of genetic testing in NSCLC treatment. One significant issue is the delays in testing due to the complex and time-consuming nature of genetic analysis. Traditional PCR tests, while relatively quick, are limited in scope, requiring supplementary tests to detect other mutations. In contrast, NGS testing, though more comprehensive, can take several days or even weeks to generate results, potentially delaying the initiation of targeted therapies.

The turnaround time for genetic testing results is critical, especially in the context of advanced NSCLC, where timely intervention is essential for improving survival outcomes. Delays in obtaining results can lead to the patient receiving standard chemotherapy instead of more effective personalized therapies. This delay can ultimately impact the patient's prognosis and reduce the chances of achieving a positive clinical outcome.

Moreover, data interpretation poses another challenge. The interpretation of genetic testing results requires advanced bioinformatics tools and highly trained professionals to ensure accurate diagnosis and treatment decisions. In South Korea, while the infrastructure for genetic testing is relatively advanced, there may still be a shortage of skilled personnel capable of interpreting complex genetic data accurately. Misinterpretation of genetic results or incorrect classification of mutations could lead to suboptimal treatment decisions and undermine the efficacy of personalized therapies.

The Need for Further Integration of Genetic Testing in Clinical Practice

Despite the clear benefits of genetic testing, integration into routine clinical practice remains inconsistent across different healthcare settings in South Korea. While leading cancer centers and academic institutions have adopted genetic testing as part of standard practice, smaller, regional hospitals or clinics may still lack the necessary resources or infrastructure to perform comprehensive genetic testing. This disparity in access to genetic testing across various healthcare settings means that patients in certain regions may not benefit from the latest advancements in precision oncology.

Moreover, there is a need for standardized guidelines and protocols for integrating genetic testing into the treatment of NSCLC. While genetic testing is increasingly recommended in clinical guidelines, its routine implementation across all oncology departments requires harmonization of testing protocols, consistency in interpretation, and clear treatment algorithms. A lack of uniformity in the application of genetic testing can lead to variations in care, where some patients may receive genetic testing as part of their diagnosis and treatment plan, while others may not, despite having similar clinical indications.

To facilitate broader integration, there must be more collaboration between research and clinical practice. Clinical trials and studies should focus on streamlining the processes of genetic testing and ensuring that it becomes a routine part of cancer care. Additionally, integrating genetic testing into electronic health records and clinical decision support systems can help ensure that clinicians have easy access to the necessary genetic information when making treatment decisions.

6. Patient and Healthcare Provider Perspectives

As genetic testing becomes essential in personalized treatment for Non-Small Cell Lung Cancer (NSCLC), understanding both patient acceptance and healthcare provider perspectives is crucial. Ethical concerns, particularly regarding patient autonomy, also play a key role in the broader implementation of genetic testing.

Patients' Acceptance and Understanding of Genetic Testing

In South Korea, many NSCLC patients are receptive to genetic testing as it helps identify effective treatments. They tend to prefer personalized therapies, viewing them as more targeted and less toxic than traditional chemotherapy. However, many patients struggle to understand the complexities of genetic testing, including the specific mutations being tested and their implications for treatment decisions. This gap in understanding can lead to unrealistic expectations, influencing the acceptance of personalized treatments. Additionally, concerns about the psychological impact of incidental findings, such as genetic predispositions to other conditions, highlight the need for proper counseling and support to help manage patient distress.

Perspectives of Oncologists and Healthcare Professionals

Oncologists in South Korea recognize the transformative role of genetic testing in improving treatment outcomes. Targeted therapies like EGFR inhibitors for EGFR-positive patients and ALK inhibitors for ALK-positive patients enhance progression-free survival (PFS) and overall survival (OS) while offering fewer side effects than conventional treatments. However, cost and accessibility of comprehensive tests like Next-Generation Sequencing (NGS) remain major concerns. While PCR-based tests for well-known mutations are more accessible, broader testing comes with high financial costs and requires specialized equipment.

Additionally, the interpretation of complex genetic data poses a challenge, necessitating ongoing education for healthcare providers. Integrating genetic testing into routine clinical practice, especially in smaller hospitals, is also a concern, requiring standardization of testing protocols across healthcare settings.

Ethical Concerns and Patient Autonomy

Ethical issues surrounding genetic testing in NSCLC include informed consent, privacy, and genetic determinism. Patients must be fully informed about potential outcomes and incidental findings. The confidentiality of genetic information is critical, as patients may fear discrimination from employers or insurance companies. Moreover, the risk of genetic determinism—where patients feel their fate is sealed by their genetic makeup—requires careful counseling to ensure they understand that while genetic testing provides valuable insights, it doesn't solely determine their prognosis. Lastly, equity in access to genetic testing is crucial to avoid exacerbating health disparities between urban and rural populations, ensuring all patients benefit from personalized medicine regardless of their socio-economic status.

In conclusion, while genetic testing offers immense potential in personalizing NSCLC treatment, challenges related to patient understanding, healthcare access, interpretation of data, and ethical concerns need to be addressed for its successful integration into clinical practice.

References

Hida, T., & Saito, K. (2018). The role of genetic testing in lung cancer treatment: Current status and future directions. *Journal of Thoracic Disease, 10*(3), 2054-2064.

Jänne, P. A., Yang, J. C., Kim, D. W., Planchard, D., Ohe, Y., Ramalingam, S. S., ... & Mok, T. S. (2015). Azd9291 in EGFR inhibitor–resistant non–small-cell lung cancer. *New England Journal of Medicine, 372*(18), 1689-1699.

Kim, Y. A., Kim, K. S., & Kim, S. W. (2019). Targeted therapy for non-small cell lung cancer in South Korea: EGFR mutation, ALK rearrangement, and ROS1 fusion. *Journal of Korean Medical Science, 34*(5), e38.

Lee, S. H., & Park, J. S. (2016). Recent advances in the management of advanced non-small cell lung cancer with EGFR mutations in South Korea. *Journal of Clinical Oncology, 34*(33), 4159-4167.

Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., & Ramalingam, S. S. (2017). Osimertinib or platinum-pemetrexed in EGFR T790M–positive lung cancer. *New England Journal of Medicine, 376*(7), 629-640. https://doi.org/10.1056/NEJMoa1612674

Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crino, L., Ahn, M. J., ... & Solomon, B. J. (2014). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *New England Journal of Medicine, 370*(13), 1189-1197.

Wu, Y. L., & Tiseo, M. (2019). Targeted therapy for non-small cell lung cancer: Current strategies and future directions. *Lung Cancer, 137*, 35-42.